Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Lanthanum Carbonate on Fibroblast Growth Factor 23 ( FGF23) in Chronic Kidney Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males and non-pregnant females ages 18 years of age or older~* Estimated glomerular filtration rate (GFR) between 15-60 ml/min/1.73m~* Serum phosphate \> 3.5 mg/dL~* Fibroblast growth factor 2 (FGF2) \> 100 relative units per milliliter (RU/mL)~* Corrected serum calcium \>8.0mg/dL~Exclusion Criteria:~* Current use of a phosphate binder~* Corrected serum calcium \<8.0mg/dL~* Current use of prescription-based vitamin D therapy~* Acute kidney injury in last 3 months~* Significant GI disorder~* History of allergic reaction or sensitivity to lanthanum carbonate~* History of non compliance with visits or medications that preclude study compliance in the opinion of the investigator~* Pregnant or able to become pregnant and unwilling to use a birth control method considered reliable by the principal investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lanthanum Carbonate (Fosrenol) (Type: ACTIVE_COMPARATOR): Subjects will receive the study drug Lanthanum Carbonate ( Fosrenol)
- Placebo (Type: PLACEBO_COMPARATOR): Subject will receive placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).